Literature DB >> 32613596

Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event.

Shirley V Wang1, Kristina Stefanini2, Edwin Lewis3, Sophia R Newcomer4, Bruce Fireman5, Matthew F Daley4,6, Jason M Glanz4,7, Jonathan Duffy8, Eric Weintraub8, Martin Kulldorff2.   

Abstract

INTRODUCTION: Childhood immunization schedules often involve multiple vaccinations per visit. When increased risk of an adverse event is observed after simultaneous (same-day) vaccinations, it can be difficult to ascertain which triggered the adverse event. This methods paper discusses a systematic process to determine which of the simultaneously administered vaccine(s) are most likely to have caused an observed increase in risk of an adverse event.
METHODS: We use an example from the literature where excess risk of seizure was observed 1 day after vaccination, but same-day vaccination patterns made it difficult to discern which vaccine(s) may trigger the adverse event. We illustrate the systematic identification process using a simulation that retained the observed pattern of simultaneous vaccination in an empirical cohort of vaccinated children. We simulated "true" effects for diphtheria-tetanus-acellular pertussis (DTaP) and pneumococcal conjugate (PCV) on risk of seizure the day after vaccination. We varied the independent and interactive effects of vaccines (on the multiplicative scale). After applying the process to simulated data, we evaluated risk of seizure 1 day after vaccination in the empirical cohort.
RESULTS: In all simulations, we were able to determine which vaccines contributed to excess risk. In the empirical data, we narrowed the association with seizure from all vaccines in the schedule to three likely candidates, DTaP, PCV, and/or Haemophilus influenzae type B (HiB) (p < 0.01, attributable risk when all three were administered together: five per 100,000). Disentangling their associations with seizure would require a larger sample or more variation in the combinations administered. When none of these three were administered, no excess risk was observed.
CONCLUSION: The process outlined could provide valuable information on the magnitude of potential risk from individual and simultaneousvaccinations. Associations should be further investigated with independent data as well as biologically based, statistically independent hypotheses.

Entities:  

Year:  2020        PMID: 32613596      PMCID: PMC7501163          DOI: 10.1007/s40264-020-00967-8

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  13 in total

1.  Orthogonal predictions: follow-up questions for suggestive data.

Authors:  Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

2.  Evaluation of potentially achievable vaccination coverage with simultaneous administration of vaccines among children in the United States.

Authors:  Zhen Zhao; Philip J Smith; Holly A Hill
Journal:  Vaccine       Date:  2016-05-07       Impact factor: 3.641

3.  Febrile Seizure Risk After Vaccination in Children 6 to 23 Months.

Authors:  Jonathan Duffy; Eric Weintraub; Simon J Hambidge; Lisa A Jackson; Elyse O Kharbanda; Nicola P Klein; Grace M Lee; S Michael Marcy; Cynthia C Nakasato; Allison Naleway; Saad B Omer; Claudia Vellozzi; Frank DeStefano
Journal:  Pediatrics       Date:  2016-06-06       Impact factor: 7.124

4.  Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.

Authors:  Robert J Yetman; Julie S Shepard; Anton Duke; Jon E Stek; Maria Petrecz; Stephanie O Klopfer; Barbara J Kuter; Florian P Schödel; Andrew W Lee
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

5.  Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.

Authors:  Yuelian Sun; Jakob Christensen; Anders Hviid; Jiong Li; Peter Vedsted; Jørn Olsen; Mogens Vestergaard
Journal:  JAMA       Date:  2012-02-22       Impact factor: 56.272

6.  'Combined vaccines are like a sudden onslaught to the body's immune system': parental concerns about vaccine 'overload' and 'immune-vulnerability'.

Authors:  Shona Hilton; Mark Petticrew; Kate Hunt
Journal:  Vaccine       Date:  2006-03-13       Impact factor: 3.641

7.  Predictive value of seizure ICD-9 codes for vaccine safety research.

Authors:  Irene M Shui; Ping Shi; M Maya Dutta-Linn; Eric S Weintraub; Simon J Hambidge; James D Nordin; Tracy A Lieu
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

Review 8.  The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.

Authors:  Michael M McNeil; Julianne Gee; Eric S Weintraub; Edward A Belongia; Grace M Lee; Jason M Glanz; James D Nordin; Nicola P Klein; Roger Baxter; Allison L Naleway; Lisa A Jackson; Saad B Omer; Steven J Jacobsen; Frank DeStefano
Journal:  Vaccine       Date:  2014-08-06       Impact factor: 3.641

9.  Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.

Authors:  Teresa M Hesley; Keith S Reisinger; Bradley J Sullivan; Erin H Jensen; Susan Stasiorowski; Cathy Meechan; Christina Y Chan; David J West
Journal:  Pediatr Infect Dis J       Date:  2004-03       Impact factor: 2.129

10.  Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.

Authors:  Scott A Halperin; Bruce Tapiéro; Marc Dionne; William Meekison; Francisco Diaz-Mitoma; Paul Zickler; Earl Rubin; Joanne Embree; Prakash Bhuyan; Andrew Lee; Minran Li; Antigona Tomovici
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.